Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 7/20 | 0.58 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 9/20 | 0.46 |
| ▸ | PIM2 | Q9P1W9 | 7/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18615008 | 0.86 | JAK2 (0.70) | JAK2NUDT1ADORA2AJAK3 | |
| SCHEMBL18615206 | 0.85 | PIM1 (0.44) | JAK2PIM1PIM2ADORA1ADORA2A | |
| SCHEMBL1691331 | 0.84 | JAK2 (0.62) | JAK2NUDT1ADORA1ADORA2AJAK3 | |
| SCHEMBL3226613 | 0.81 | JAK2 (0.74) | JAK2NUDT1PIM1PIM2ADORA1 | |
| SCHEMBL3233033 | 0.80 | JAK2 (0.60) | JAK2JAK3 | |
| SCHEMBL12517030 | 0.79 | JAK2 (0.63) | JAK2NUDT1ADORA1ADORA2AJAK3 | |
| SCHEMBL3222453 | 0.78 | JAK2 (0.55) | JAK2JAK3 | |
| SCHEMBL3226670 | 0.78 | JAK2 (0.52) | JAK2JAK3 | |
| SCHEMBL3219158 | 0.77 | JAK2 (0.54) | JAK2JAK3 | |
| SCHEMBL18615150 | 0.77 | JAK2 (0.69) | JAK2NUDT1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10604517-B2 | Bridged piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-10604517-B2 | Bridged piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20180237432-A1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-08-23 | — | — | US | disclosed |
| EP-3347363-A1 | BRIDGED PIPERIDINE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2018-07-18 | — | — | EP | disclosed |
| WO-2017042114-A1 | BRIDGED PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-16 | — | — | WO | disclosed |
| WO-2017042114-A1 | BRIDGED PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180237432-A1 | BRIDGED PIPERIDINE DERIVATIVES | HPGDS, APP, PSEN1 | JAK2 2869/4885NUDT1 523/4885PIM1 2489/4885 |
| US-10604517-B2 | Bridged piperidine derivatives | HPGDS, APP, PSEN1 | JAK2 2869/4885NUDT1 523/4885PIM1 2489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.